Population Selection
Identify optimal subpopulations based on historical evidence, biomarkers, and predictive modeling.
Achieve Clinical Trial Excellence with Artificial Intelligence
Life sciences organizations struggle with clinical trial design due to fragmented data systems, siloed decision-making processes, and limited analytics capabilities.
This disjointed approach leads to suboptimal patient selection, inappropriate endpoints, and disconnected portfolio strategies, with over 30% of trials failing due to design issues alone.
Without a data-driven methodology to integrate historical evidence, real-world data, and regulatory precedents into cohesive trial designs, companies face extended timelines, escalating costs, and diminished portfolio value in an increasingly competitive market landscape.
Identify optimal subpopulations based on historical evidence, biomarkers, and predictive modeling.
Design endpoints that balance regulatory requirements, topic relevance, and statistical power.
Analyze market and portfolio fit to differentiate trial designs from existing competitors.
Enhance patient-trial matching through AI-powered document analysis and conversational interfaces.
Evaluate clinical design processes and identify high-impact opportunities.
Design the AI strategy and framework that supports data-driven trial design decisions.
Configure platform workflows and validate with real-world scenarios.
Deploy with training, adoption support, and roadmap for expansion.
Continuously refine models and extend to new therapeutic areas.
Allergan
Availity
Care Logistics
This solution integrates historical trial data, real-world evidence, and regulatory precedents to optimize trial design decisions across multiple dimensions:
We endeavor to #Staycurious in every aspect of our work. We put together some FAQs that we've heard from colleagues and customers.